Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HJ Science IPO: Late Move in Crowded Market Dampens Future Growth Prospect

HJ Science (华健未来) Pre-IPO: Thoughts on Valuation

HJ Science (华健未来) Pre-IPO: Clinical Evidence Needed for Pipeline Breadth

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

<ul>
<li>HJ Science, an autoimmune, metabolic and oncology drug developer, launched its Hong Kong IPO to raise USD143m.</li>
<li>In this note, we look at the deal terms and recap our valuation thoughts for the company.</li>
<li>We also look at the main reason that caps the return of the deal.</li>
</ul>


HJ Science, an autoimmune, metabolic and oncology drug developer, launched its Hong Kong IPO to raise USD143m.
In this note, we look at the deal terms and recap our valuation thoughts for the company.
We also look at the main reason that caps the return of the deal.


HJ Science (华健未来) IPO: Analysis of Deal Terms